Acadia Pharmaceuticals Inc. shares were on a decline in after-hours trading on Monday as Wall Street learned that the company’s supplemental treatment for schizophrenia failed to meet key benchmarks in a late phase trial. The company’s President Serge Stankovic, M.D., M.S.P.H., stated that Pimavanserin, “did not a achieve a statistically significant reduction” in symptoms in … Continue reading “Acadia Pharmaceuticals Takes a Nose Dive After Schizophrenia Drug Fails”
